141 results about "Cerebral ischaemia" patented technology

The invention discloses an intelligent decision-making method for a cerebral ischemia drug administration time window, and relates to the technical field of intelligent decision-making. The method comprises the following steps: S1, acquiring parameters, and setting a cerebral ischemia drug configuration scheme; s2, extracting a medicine characteristic parameter set and a medicine taking influence parameter set; s3, calculating a drug combination risk parameter set; s4, performing hierarchical classification processing on the drug combination risk parameter set, and performing drug correlation analysis; s5, performing weighted fusion on a correlation analysis result in combination with a drug influence attenuation rule, generating a drug administration time window evaluation parameter, and adding a label; and S6, according to the parameters, the labels and the configuration scheme, generating a cerebral ischemia drug administration time window intelligent decision scheme, and performing storage and backup. According to the method, by combining directional extraction of the drug characteristic parameter set and the drug taking influence parameter set with Pearson correlation algorithm screening, decision errors caused by data deviation are avoided.

The invention relates to an astragaloside-loaded astragalus membranaceus exosome which is prepared by the following steps: crushing astragalus membranaceus, and filtering to obtain juice; performing multi-step differential centrifugation to obtain supernate; carrying out ultrafiltration and centrifugation, and collecting the precipitate; adding to the upper layer of a sucrose stepped gradient solution, centrifuging, and collecting part of strips; after dilution, centrifuging, discarding the supernatant, precipitating, and removing cane sugar to obtain the astragalus membranaceus exosome; the radix astragali exosome loaded with the astragaloside is obtained by mixing the radix astragali exosome with the astragaloside and carrying out ultrasonic treatment or co-incubation, and can be used for preparing medicines for specifically inhibiting cGAS / STING pathway excessive activation in cerebral ischemia reperfusion injury and downstream NLRP3 inflammasome mediated pyroptosis and preparing medicines for protecting and repairing mitochondria in the cerebral ischemia reperfusion injury. The homologous astragalus membranaceus exosome is used as a natural carrier, the blood-brain barrier is effectively overcome, and the enrichment concentration and bioavailability of astragaloside in a cerebral ischemia area are remarkably improved.

The invention relates to a bionic nano CO generator as well as preparation and application thereof, belongs to the technical field of medicines, and solves the problem that a CO delivery system which can synergistically promote neuroprotection and neurogenesis and has brain targeting and controlled release capabilities is urgently required to be developed at present. According to the technical scheme, the bionic nano CO generator comprises a drug-loaded particle inner core and a covering film, the drug-loaded particle inner core comprises hollow mesoporous CeO2 nano particles and MnCO loaded on the hollow mesoporous CeO2 nano particles, and the covering film is a macrophage membrane and wraps the drug-loaded particle inner core. The compound is used for apoplexy treatment administration by integrating neuroprotection and enhancing innovative dual channels of endogenous nerve growth, and is expected to significantly reduce brain injury after cerebral apoplexy and restore neurological functions so as to relieve the worry about high death rate and long-term disability after cerebral ischemia-reperfusion injury.

The invention relates to the technical field of biological medicine, in particular to 7-dehydrocholesterol liposome and application thereof. According to the invention, a biological membrane modified liposome is constructed, and the biological membrane modified liposome comprises an ROS responsive liposome, a neutrophile granulocyte membrane and a renal tubular epithelial cell membrane; the biofilm modified liposome has an active oxygen species (ROS) responsive release function and a dual targeting capability, has the advantages of an integrated drug effect carrier, ROS triggered release, dual bionic targeting, strong target cell uptake and multi-mechanism ferroptosis resistance, and can be used for preparing the biofilm modified liposome. The compound can be used for treating ferroptosis related diseases such as acute kidney injury, myocardial ischemia-reperfusion injury and cerebral ischemia-reperfusion injury, and has wide clinical popularization value.

This invention discloses a class of aminosalicylic acid derivative compounds, their pharmaceutical compositions, and uses. The aminosalicylic acid derivatives of this invention can significantly improve ischemic symptoms in rats with a cerebral ischemia-reperfusion model, and these compounds have broad application prospects in the preparation of drugs for the prevention and treatment of stroke.

A traditional Chinese medicine formula for treating blood vessel clogging belongs to the field of traditional Chinese medicine formulas, and comprises the following main raw materials: 29-31 parts of black pearl, 11-13 parts of codonopsis pilosula, 7-9 parts of saffron crocus, 8-10 parts of angelica sinensis, 190-210 parts of leek, 9-11 parts of pseudo-ginseng, 37-43 parts of hawthorn, 95-105 parts of astragalus membranaceus, 18-22 parts of kudzu vine root, 8-10 parts of peach kernel, 8-10 parts of prepared rehmannia root, 9-11 parts of radix rehmanniae, 11-13 parts of white paeony root, 3 parts of red ginseng, 9-11 parts of radix ophiopogonis, 14-16 parts of spina date seed, 11-13 parts of Chinese yam, 14-15 parts of schisandra chinensis, 9-11 parts of polygonum multiflorum, 7-9 parts of cinnamon, 18-21 , 13-15 parts of anise and 12-14 parts of rhizoma polygonati. The traditional Chinese medicine composition has an obvious improvement effect on coronary artery insufficiency, myocardial ischemia, mitral valve, tricuspid valve, aortic valve regurgitation, chronic heart failure, patients needing operation bypass stenting, angina pectoris, myocardial infarction sequelae, cerebral ischemia, cerebrovascular sequelae and other symptoms caused by cardiac insufficiency, the dosage is small, the effect is fast, the cure rate is high, relapse is not prone to occurring, and the traditional Chinese medicine composition is suitable for clinical application. The effects of tonifying qi and activating blood, dredging channels and relieving pain, eliminating phlegm and removing blood stasis, tonifying heart and soothing nerves and the like can be achieved.

The invention discloses an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure and a preparation method and application thereof. The chemical structural formula of the ferroptosis inhibitor is shown as a formula 1 or a formula 2. The ferroptosis inhibitor can inhibit ferroptosis caused by a ferroptosis inducer and can reduce the level of active oxygen in cells. Nerve injury caused by cerebral ischemia reperfusion can be relieved, and symptoms of neurological diseases such as Alzheimer's disease and Parkinson's disease can be relieved; compared with a ferroptosis inhibitor Ferrostatin-1, the aryl alkyl amine compound disclosed by the invention has better metabolic stability and is suitable for in-vivo drug effect evaluation. Therefore, the novel aryl alkyl amine compound provided by the invention has a very good application value in treatment of neurological diseases related to ferroptosis.

The application discloses an indigo red derivative, a preparation method of the indigo red derivative, and application of the indigo red derivative in preparation of an anti-cerebral ischemia neuroprotective drug or a drug component. The indigo red derivative has good anti-cerebral ischemia neuroprotective activity, can overcome defects of existing active ingredients, such as easy bleeding, difficulty in penetrating a blood-brain barrier, poor oral bioavailability, low selectivity, and high neurobehavioral toxicity, and can be used as a cerebral neuroprotective active ingredient for treatment of ischemic cerebral stroke. According to an animal experiment of cerebral neuroprotective activity screening, it can be seen that after the compound is given preventively, the survival time of acute cerebral ischemia mice can be obviously prolonged, and the compound has good anti-cerebral ischemia neuroprotective effect.

The invention relates to the technical field of medicines, in particular to application of DP-b99 and a derivative thereof in preparation of a medicine for treating cerebral ischemia mechanical thrombus extraction reperfusion injury. On the basis of mechanical thrombus extraction and reperfusion of cerebral ischemia, DP-b99 is combined to reduce mechanical thrombus extraction and reperfusion injury of cerebral arterial thrombosis, so that the inflammation level of brain tissues can be reduced, the volume of cerebral infarction can be reduced, the injury of the brain tissues can be effectively reduced, and the treatment effect is remarkable.

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a PSD-95 PDZ2 peptidomimetic inhibitor and application thereof. A series of compounds are designed and synthesized by taking a tetrapeptide ETAV as a template, a structure-activity relationship of the compounds with PSD-95 PDZ2 is systematically studied, and an optimal compound 32-2, i.e., the PSD-95 PDZ2 peptidomimetic inhibitor, is screened, a structural formula of which is shown as formula (I), the PSD-95 PDZ2 peptidomimetic inhibitor has very excellent plasma stability, and exhibits significant neuroprotective activity in in-vivo and in-vitro biological activity evaluation, significantly reduces cerebral infarction caused by cerebral ischemia-reperfusion injury, and can be used for preparing a drug for treating ischemic stroke. (I).

The invention belongs to the technical field of biological medicines, and particularly discloses a self-assembled nano preparation coated with a macrophage membrane as well as a preparation method and application of the self-assembled nano preparation. According to the nano preparation, nano particles formed by self-assembly of epigallocatechin gallate (EGCG), ferric chloride (FeCl3) and edaravone (EDV) serve as a core, and the outer layer of the nano preparation is coated with a macrophage membrane. The preparation method is a one-pot method and comprises the following steps: mixing and self-assembling EGCG, FeCl3 and EDV in a phosphate buffer solution, carrying out centrifugal purification, and carrying out ultrasonic fusion with a macrophage membrane. The nano preparation is uniform in particle size, has excellent free radical scavenging capacity and antioxidant activity, can effectively pass through a blood-brain barrier and target a cerebral ischemia reperfusion injury area, and shows a remarkable effect in preparation of drugs for treating cerebral arterial thrombosis.

The invention discloses a strain of lactobacillus acidophilus for treating chronic cerebral ischemia, which is preserved in the China Center for Type Culture Collection (CCTCC) and has the preservation number of CCTCC NO: M 20251505. Animal experiments show that the strain can reduce the death rate of chronic cerebral ischemia model mice and improve neurological impairment, motion coordination and spatial learning and memory ability of the chronic cerebral ischemia model mice. Mechanism research shows that the strain can increase histone acetylation and BDNF secretion by inhibiting the activity of astrocyte HDAC1, and meanwhile, can inhibit an NF-kappa B signal channel and reduce inflammatory factor release by activating a microglial cell GPR120 receptor, so that a neuroprotective effect is achieved through an'intestine-brain axis'. The invention provides a new candidate strain for the development of microbial preparations for preventing and / or treating chronic cerebral ischemia and related cognitive impairment.

The invention discloses application of a PLAU signal channel inhibitor in treating ischemic cerebral apoplexy and a pharmaceutical composition, and belongs to the field of biological medicine. The PLAU signal channel inhibitor inhibits the activation of an NF-kappa B channel and reduces the generation of inflammatory factors (IL-1beta, IL-6 and TNF-alpha) by inhibiting the expression of PLAU protein in cells. Experiments prove that the PLAU signal channel inhibitor can remarkably improve related pathological indexes of ischemic cerebral apoplexy, the cerebral infarction area is reduced by more than or equal to 30%, the vascular endothelial cell activity is improved by more than or equal to 25%, the inflammatory factor level is reduced by more than or equal to 40%, and the protective effect on cerebral ischemia reperfusion injury is superior to the overall effect of a traditional Chinese medicine compound. The invention provides a clear mechanism basis for targeted therapy of ischemic cerebral apoplexy.

The invention belongs to the technical field of cell culture, and discloses a cell culture device for an experiment for treating cerebral ischemia stroke based on long non-coding RNA, the cell culture device comprises an incubator, a cross-shaped partition plate is fixedly connected in the incubator, a culture mechanism is arranged in the incubator, the culture mechanism comprises four stabilizing assemblies and a temperature control assembly, and the temperature control assembly is connected with the cross-shaped partition plate. The stabilizing assembly and the temperature control assembly are matched for use, the stabilizing assembly comprises sliding rails, the sliding rails are fixedly connected to the interior of the incubator, and sliding blocks are symmetrically and slidably connected to the interiors of the two sliding rails. By arranging the culture mechanism, stable, independent and environment-controllable parallel culture is carried out on a plurality of experimental samples in the same culture box, the culture dish can be stably clamped and fixed to prevent accidental overturning, and the culture dish has the partitioned independent temperature control capability; therefore, stable, reliable and flexible hardware support is provided for related frontier biomedical research.

This invention relates to the field of biomedical technology, specifically to the application of OGR1 as a target in the preparation of drugs for treating cerebral ischemia. This invention utilizes a viral vector to overexpress OGR1 in neurons surrounding infarcts. Ogr1 Treatment with OGR1 agonists can significantly promote the recovery of motor function and nerve repair after cerebral ischemia, and the treatment time window is at least 3-7 days after cerebral ischemia, which significantly enhances the treatment effect of cerebral ischemia.

The present disclosure relates to compositions comprising N, N-dimethyltryptamine or a salt thereof and N, N-dimethyltryptamine or a salt thereof, pharmaceutical compositions comprising a combination of N, N-dimethyltryptamine or a salt thereof and N-acylethanolamine or a salt thereof with at least one pharmaceutically acceptable carrier and / or excipient and their use in a method of treating cerebral ischemia or hypoxia by administering the composition in a therapeutically effective amount to a subject in need thereof.

Disclosed are an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure, a preparation method therefor, and an application thereof. The chemical structural formula of the ferroptosis inhibitor is as shown in formula (1) or formula (2). The ferroptosis inhibitor is capable of inhibiting ferroptosis caused by a ferroptosis inducer, and reduces the level of intracellular reactive oxygen species. The ferroptosis inhibitor reduces neurological damage caused by cerebral ischemia-reperfusion, and alleviates symptoms of neurological disorders such as Alzheimer's disease and Parkinson's disease. Compared to the ferroptosis inhibitor Ferrostatin-1, the arylalkylamine compound exhibits better metabolic stability and is suitable for in-vivo efficacy evaluation. Therefore, the novel arylalkylamine compound provided by the present invention demonstrates great application value in the treatment of ferroptosis-related neurological disorders.

The application belongs to the technical field of medicine, and particularly relates to a muscone derivative, a preparation method and application thereof. The muscone derivative cyclopentadecanedione monoxime has obvious advantages over muscone and other derivatives in improving the MCAO rat mNSS score, microcirculation blood flow, reducing the cerebral infarction rate, the cortical and hippocampal neuron necrosis rate, and the brain water content, and increasing the SOD and CAT contents of the rat brain tissue which are abnormally reduced due to ischemia, and is a potential effective drug for cerebral ischemia-reperfusion injury.

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

The invention relates to an application of an active peptide LLAPP in preparation of medicines for preventing and / or treating ulcerative colitis, cerebral ischemia and / or myocardial ischemia. According to the present invention, the LLAPP administration UC mouse animal experiment and the lipopolysaccharide (LPS) stimulation RAW264.7 cell experiment verify that the LLAPP can effectively relieve the ulcerative colitis, the cerebral ischemia and the myocardial ischemia symptoms, can be used as the ulcerative colitis, the cerebral ischemia and the myocardial ischemia treatment drug, can significantly improve the colitis symptoms, can alleviate the cerebral ischemia and myocardial ischemia injury, and can be used as the drug for treating the ulcerative colitis, the cerebral ischemia and the myocardial ischemia injury. Good development and application prospects are realized.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

The invention belongs to the technical field of gene drugs, and particularly relates to application of lncRNA-AU020206 in preparation of drugs for treating cerebral arterial thrombosis, the key effect of the lncRNA-AU020206 in occurrence and development of the cerebral arterial thrombosis is disclosed for the first time, and it is clear that the lncRNA-AU020206 activates ferroptosis signal channels through negative regulation of SLC7A11 expression, so that cerebral ischemia reperfusion injury is aggravated. In-vivo and in-vitro experiments prove that the levels of MDA, ROS and Fe < 2 + > can be remarkably reduced by silencing the lncRNA-AU020206, the expression of GPX4 and SLC7A11 can be up-regulated, the cerebral infarction volume and neurological dysfunction can be reduced, and cerebral edema and apoptosis can be improved. Therefore, the lncRNA-AU020206 not only can be used as a new target for treating the cerebral arterial thrombosis, but also can be used for developing a related diagnostic kit, and has remarkable clinical application prospect and market value.

This invention relates to the fields of pharmaceuticals and nanomedicine, specifically disclosing the preparation of a dual-targeting liposome drug delivery system and its application in stroke. The dual-targeting liposome drug delivery system comprises neutrophils, artemisinin, edaravone, and liposomes. The liposomes co-load artemisinin and edaravone, and their surfaces are modified with sialic acid derivatives and phosphatidylserine to form liposome nanomedicines. The neutrophils act as carriers, transporting the drug across the brain border (BBB) ​​and targeting it to the ischemic brain region. This dual-targeting strategy achieves precise two-stage drug delivery to the ischemic brain region. This delivery system can inhibit NLRP3 inflammasome activation, reduce pyroptosis, and promote microglial polarization towards the M2 anti-inflammatory phenotype, thereby effectively treating cerebral ischemia-reperfusion injury or ischemic stroke.

An arylalkylamine ferroptosis inhibitor based on an edaravone structure, and a preparation method therefor and a use thereof. The structural formula of the ferroptosis inhibitor is as shown in the following formula I, formula II, or formula III: formula I, formula II, formula III. The ferroptosis inhibitor has strong ROS scavenging ability and an inhibitory effect on lipid peroxidation, can inhibit ferroptosis caused by an ferroptosis inducer, and can reduce cerebral ischemia and nerve damage caused by cerebral ischemia, and alleviate symptoms of neurological diseases such as Parkinson's syndrome. On the basis of the ferrostain-1 / edaravone structure, the provided arylalkylamine ferroptosis inhibitor can exert a synergistic effect by means of multiple effects to treat ferroptosis-related diseases and can also expand the use of edaravone, thereby providing a candidate compound for subsequent drug research and development.

The present application relates to a kind of nano-drugs with eNOS-like enzyme activity and its preparation method and application, belong to nano-drug technical field.Solve the technical problems that drug cannot pass through blood-brain barrier and cannot simultaneously inhibit neuron calcium overload, reduce mitochondrial damage and endoplasmic reticulum stress, inhibit inflammatory storm and other multiple effects in prior art.The nano-drug of the present application is the NO embedded molybdenum sulfide nanomaterial obtained by introducing S-nitroso group on the surface of small particle molybdenum sulfide.The nano-drug prepared by the present application has super strong antioxidant activity and stable NO release capacity, can effectively target CIRI brain tissue damage and stable release pure NO, can effectively treat cerebral ischemia-reperfusion injury, while improving intracellular Ca 2+ Overload, oxidative stress and inflammatory storm, can effectively protect neuron mitochondria from overload Ca 2+ And mtROS Damage, and significantly restore mitochondrial function in CIRI and other advantages.

A cycloheptenone adduct of flavanols and stilbene compounds as shown in formula (I), its preparation method, and its use in treating cerebral ischemia. The compound of this invention has a simple preparation method and exhibits good neuroprotective activity.